All News

Would you use #CAR-T in #polyrefractory #RA #EULAR2025 @RheumNow @eular_org

Janet Pope Janetbirdope ( View Tweet)

POS0150: From 12 RA registries, JAKi starts fell by ~13% after FDA safety alerts. Tofa & bari took biggest hits; upa growth slowed but offset losses. Real-world prescribing adapts—but doesn’t abandon. @RheumNow #EULAR2025 https://t.co/QZ5haW2vhX

Links:

Jiha Lee JihaRheum ( View Tweet)
Ultrasound for ILD detection in RA 🫁 Sens 88.6 Spe 92.8 NPV 91.4 PPV 90.7 While if abnormal or high suspicion, HRCT should be the reference, I see this as an interesting tool in clinics for quick screening POS0180 #EULAR2025 @RheumNow https://t.co/pUy0ki7Y6S

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
#HOT topic Lung 🫁 #ultrasound for #RA #ILD #LUS B lines vs HRCT Single site 🇫🇷 study V sensitive & specific 🤔needs standardization & comparison in other groups Abst#POS-180 #EULAR2025 @RheumNow @eular_org https://t.co/PwGE4rgk40

Links:

Janet Pope Janetbirdope ( View Tweet)
Software enhances treat to target outcomes for #RA GoTreatIT P0S0750 ##EULAR2025 @RheumNow https://t.co/GpihWr5KLA

Links:

Bella Mehta bella_mehta ( View Tweet)
Does having a synovitis in a specific joint predicts Rx damage in that same joint? Yes Can US synovitis predict Rx progression better than clinical synovitis at the joint level? Not really At 1 year, only US synovitis is, both B-mode and Doppler ass w/ Rx prog, in particular https://t.co/Wu6dDqIUYn

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Tenosynovitis of 5th compartment independently associated w/ D2T RA in a cohort of 90+ pts compared to established RA Erosions, Tenosynovitis and Synovitis non associated with D2T phenotype It’d be interesting to see if this could predict D2T evolution in early RA pts POS0185 https://t.co/faruOr3HhJ

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
New dual-action RA drug? OP0193: CPL’116 targets both JAK & ROCK. In 12-wk RCT, highest dose improved DAS28-CRP, joint counts & pain, with clean labs. Is this a future option for RA-ILD or patients with comorbid CVD risk? #EULAR2025 @RheumNow

Jiha Lee JihaRheum ( View Tweet)

Ph 2 RCT CPL'116 dual inhibition JAK/ROCK 106 MTX IR pts wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs. PBO 75% >= AEs, SAE 2: 1 MI, 1 bladder cancer Authors suggest absence of lipids/LFTs disruption compared to other JAKs Ph3 is awaited!! #OP0193 #EULAR2025 https://t.co/TnnM410LfM

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Combination of LEF and MTX in RA: Yay or Nay? #EULAR2025 @RheumNow

Aurelie Najm AurelieRheumo ( View Tweet)

OP0195: MTX+LEF isn’t commonly used—but could it be a viable option after all? In >1,100 RA pts, no link to liver fibrosis (FIB-4/APRI), modest ALT ↑, and fewer hospitalizations. real-world safety data worth a second look. @RheumNow #EULAR2025

Jiha Lee JihaRheum ( View Tweet)

Premature death in RA still exists, and varies according to race/ethnicity demographic groups Nationwide US CDC's MCoD database analysis -Mortality rates 11x higher American Indians 3x higher Black or African American people -Median age at death with RA 9-10 years younger https://t.co/FTRWPk7Wz0

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
RA-related premature mortality highest in American Indians--> 3.6x odds of death in <65 vs White peers, w/ no improvement over 22 yrs. COVID widened the gap. Need to address structural & social drivers of early death in RA, & wider health disparities. @RheumNow #EULAR2025 #OP0197

Mrinalini Dey DrMiniDey ( View Tweet)

Yes, it is relevant to ask patients about physical joint strain in RA and propose strain specific interventions In ACPA+ RA pts for each 10% increase in strain, 7% increase in SJC44 and 5% MRI inflammation POS0166 #EULAR2025 @RheumNow https://t.co/jwpi7S8JTW

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
We should address patients anxiety at RA diagnosis: cohort 250+ newly diagnosed RA pts -49% reported anxiety -41% by 3 months Anxiety asso w/ CDAI, PROs and 3-5 fold increase in prescription of bio/tsDMARDs Analysis reasonably adjusted POS0163 #EULAR2025 @RheumNow https://t.co/2gejEkRQhO

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
BioDMARDs reduce polyimmunity in RA Danish Registry based cohort study 5 yrs follow up 25000+ pts Polyimmunity in csDMARDs treated group 2.2% vs. 1.7% in bioDMARDs group HR 0.74 Most frequent autoimmune thyroid disease POS0161 #EULAR2025 @RheumNow https://t.co/9T0mhoUuqs

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
There is still hope for vagal nerve stimulation in RA! RCT RESET-RA 240+pts multibioIR Implantable cervical device Meets Primary endpoint ACR 20 wk12 Subgroup 1 prior bioDMARD ACR 20 wk12 46% vs 19% sham EULAR Good response 61% vs 42% sham Wk 12 SAE rate 1.7% #OP0190 #EULAR2025 https://t.co/DCON01XXgd

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Leeds study of 223 ACPA+ Arthralgia pts w quant. MRI of hand showing tenosynovitis (34% at baseline) doubled the risk of progression to RA. Total tenosynovitis Volume = incr. RA risk #EULAR2025 POS0472 https://t.co/eT0wbhp1uN
Dr. John Cush RheumNow ( View Tweet)
Hepcidin detected in synovial membrane and fluid in RA, PsA, and OA. Monocytes were the main source. IL-6, IL-10, IL-17, M-CSF induced hepcidin via JAK-STAT pathway. Hepcidin reduced osteoclastogenesis but correlated with synovial neutrophils and CXCL1 induction. Functional dual https://t.co/ZjUtTYPre8

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
VEGF-Grab (PB101/PB102), dual VEGF/PlGF decoy receptor, inhibited angiogenesis, RA-FLS invasion, and Th17 cell differentiation in RA and MS models. PB102 reduced IL-17 and GM-CSF co-expressing Th17 cells, suppressed pannus and joint destruction in CIA, and outperformed IFN-β in https://t.co/qhVRYT4RbK

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×